KQED's Joshua Johnson talks with Dr. Andrew Zolopa, director of the Positive Care Clinic at Stanford about the benefits -- and risks -- of a drug that can help prevent people from acquiring HIV.
Peninsula-based drugmaker Gilead Sciences received permission from the FDA on Monday to sell its landmark daily pill, Truvada, to HIV-negative people as a way of protecting them from getting infected. Some researchers call it a step toward eradicating AIDS, while others fear it may be a step back from years of encouraging safer sex habits.
Read more at: www.kqed.org
